Stay updated on iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial

Sign up to get notified when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The website’s displayed revision number changed from v3.8.0 to v3.8.1; the clinical study record remains unchanged.
    Difference
    0.1%
    Check dated 2026-11-17T17:13:44.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The record presents details of the NIPICOL phase II study of nivolumab and ipilimumab for metastatic colorectal cancer, including its eligibility criteria, treatment plan, outcomes, locations, and study status.
    Difference
    53%
    Check dated 2026-11-10T16:31:05.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the study record remains unavailable behind a 403 error.
    Difference
    0.2%
    Check dated 2026-11-03T16:47:12.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    A site-wide NIH transition notice appears above the ClinicalTrials.gov page, and the site revision advances from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error.
    Difference
    1%
    Check dated 2026-10-20T19:16:17.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-06T21:36:20.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    The study record page now shows a 403 Forbidden error, replacing the previous content. This indicates that access to the page is blocked and the normal study details are not visible.
    Difference
    19%
    Check dated 2026-09-22T23:54:02.000Z thumbnail image

Stay in the know with updates to iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.